Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Takeda scraps late-stage amyloidosis study

Written by: | no-reply@reuters.com | Dated: Wednesday, June 5th, 2019

 

(Reuters) – Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals.

Amyloidosis is a rare disease caused by an abnormal build up of a substance called amyloid in organs.

Treatment with Takeda’s Ninlaro, in combination with dexamethasone, did not show a significant improvement in patients’ overall hematologic response compared to standard of care regimens, the company said.

U.S.-listed shares of Takeda were down about 2% at $16.5 in after-hours trading.

 

Reporting by Manojna Maddipatla in Bengaluru; Editing by James Emmanuel

 

Reuters source:

https://www.reuters.com/article/us-takeda-pharma-study/takeda-scraps-late-stage-amyloidosis-study-idUSKCN1T62P5

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom